The global Sandhoff Disease Therapeutics Market is expected to garner a market value of US$10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Sandhoff Disease Therapeutics registered a CAGR of 4% in the historical period 2018 to 2022.
According to the latest studies, Sandhoff disease is a rare disorder that is estimated to affect 1 in 1,000,000 individuals. The increasing demand for these treatments is expected to lead to the development of new and innovative treatments, which will drive the growth of the market in the coming years.
Gene therapy is being researched as a potential treatment for Sandhoff disease. The therapy works by introducing a functional copy of the missing enzyme into the patient’s cells, thereby restoring the ability to break down GM2 ganglioside. This can potentially slow or stop the progression of the disease, and improve the patient’s quality of life.
Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16729
Key Takeaways from the Market Study
- From 2018 to 2022, the Sandhoff Disease Therapeutics market grew at a CAGR of 4%.
- The global Sandhoff Disease Therapeutics market is expected to grow with a 6% CAGR during 2023 to 2033.
- As of 2033, the Sandhoff Disease Therapeutics Market is expected to reach US$ 17.91 Million.
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 40% market share for the Sandhoff Disease Therapeutics market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Sandhoff Disease Therapeutics.” says an FMI analyst
Market Competition
Key players in the market include pharmaceutical companies such as Bioasis Technologies Inc, Nuo Therapeutics Inc, Sio Gene Therapies, Inc., INTRABIO IRELAND LIMITED, Sanofi, ROIVANT SCIENCES LTD, Azafaros, Polaryx Therapeutics, Abbott Medtronic, and Merck & Co., Inc. along with healthcare providers and technology companies among other global players.
- In November 2020, Axovant Gene Therapies Ltd., a company developing gene therapies, announced that the FDA has cleared its Investigational New Drug Application to start a registrational study of AXO-AAV-GM2 gene therapy for Tay-Sachs and Sandhoff diseases. AXO-AAV-GM2 is the first gene therapy to receive IND clearance for these diseases. The FDA letter confirms that all issues related to the clinical hold have been resolved. This marks a significant moment for the GM2 gangliosidosis community and is the second IND clearance for Axovant’s gene therapy pipeline in the last year, with the first being AXO-AAV-GM1 for GM1 gangliosidosis.
Need more information about Report Methodology? Click here@ https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16729
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Sandhoff Disease Therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Type, Therapy, End-Users and Region.
Key Segments Profiled in the Sandhoff Disease Therapeutics Industry Survey
Therapy:
- Gene Therapy
- Enzyme Replacement Therapy
- Stem Cell Therapy
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16729
Type:
- Acute infantile Sandhoff disease
- Subacute juvenile Sandhoff disease
- Late-onset Sandhoff disease
End-Users:
- Hospitals
- Homecare
- Specialty Clinics
More Trending Reports by Future Market Insights:
Nuclear Medicine Equipment Market
Enzyme Replacement Therapy Market
About FMI:
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
